Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial

<strong>Background: </strong>There are limited data on the immunogenicity of coronavirus disease 2019 (COVID-19) vaccines in African populations. Here we report the immunogenicity and safety of the ChAdOx1 nCoV-19 (AZD1222) vaccine from a phase 1/2 single-blind, randomised, controlled tr...

Full description

Bibliographic Details
Main Authors:	Hamaluba, M, Sang, S, Orindi, B, Njau, I, Karanja, H, Kamau, N, Gitonga, J, Mugo, D, Wright, D, Nyagwange, J, Kutima, B, Omuoyo, D, Mwatasa, M, Ngetsa, C, Agoti, C, Cheruiyot, S, Nyaguara, A, Munene, M, Mturi, N, Oloo, E, Ochola-Oyier, L, Mumba, N, Mauncho, C, Namayi, R, Davies, A, Tsofa, B, Nduati, E, Aliyan, N, Kasera, K, Etyang, A, Boyd, A, Hill, A, Gilbert, S, Douglas, A, Pollard, A, Bejon, P, Lambe, T, Warimwe, G
Other Authors:	COV004 Vaccine Trial Group
Format:	Journal article
Language:	English
Published:	F1000Research 2023

Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial

Similar Items